Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15655487 | 0.78 | MAPK1 (0.33) | MAPK1IDO1TDO2TSHRDPP4 | |
| SCHEMBL1059489 | 0.78 | EDNRB (0.40) | MAPK1ALDH1A1KCNN4ALOX15 | |
| SCHEMBL28058949 | 0.78 | MAPK1 (0.33) | MAPK1IDO1TDO2TSHRDPP4 | |
| SCHEMBL2325083 | 0.78 | TSHR (0.37) | MAPK1IDO1TDO2TSHRDPP4 | |
| SCHEMBL1059487 | 0.78 | EDNRB (0.40) | MAPK1ALDH1A1KCNN4ALOX15 | |
| SCHEMBL544573 | 0.74 | TSHR (0.39) | MAPK1TSHRDPP4ALDH1A1KCNN4 | |
| SCHEMBL1059491 | 0.74 | MAPK1 (0.34) | MAPK1IDO1TDO2ALDH1A1KCNN4 | |
| SCHEMBL29255951 | 0.74 | KCNA5 (0.34) | MAPK1IDO1TDO2ALDH1A1ALOX15 | |
| SCHEMBL5272340 | 0.74 | CYP2D6 (0.35) | MAPK1IDO1TDO2ALDH1A1ALOX15 | |
| SCHEMBL1059507 | 0.74 | EDNRB (0.42) | MAPK1TSHRKCNN4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1760085-B1 | PROCESS FOR PRODUCTION OF ALKYLTIN ALKOXIDES | ASAHI KASEI CHEMICALS CORP (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-7541482-B2 | Process for production of alkyltin alkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080275262-A1 | Process for Production of Alkyltin Alkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1760085-A1 | PROCESS FOR PRODUCTION OF ALKYLTIN ALKOXIDES | Asahi Kasei Chemicals Corporation (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275262-A1 | Process for Production of Alkyltin Alkoxides | ALK, MOGAT2, SOAT2 | MAPK1 1221/4885IDO1 1650/4885TDO2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.